News Parabilis prices IPO at an ambitious $475 million Parabilis has set the terms of its IPO, seeking to raise a hefty $475m for phase 3 trials of its lead drug for desmoid tumours.
News NewLimit raises $435m for liver trials, and other financings Longevity biotech NewLimit's $435m Series C heads this week's round-up of biotech venture capital financings.
News GHO, CBC merge to create largest healthcare investment firm Two top healthcare investors – UK-based GHO and CBC Group of Singapore – have announced a merger to create a massive player in the category.
News Isomorphic raises $1.2bn for AI drug hunt Isomorphic Labs has added to the lustre attached to its AI-powered drug discovery engine by raising an eye-watering $1.2 billion in a Series B round.
News Windward raises $165m for TSLP drug, and other biofinancings Recent biotech financings include nine-figure rounds for Windward Bio and Coultreon, with Vivacta, Kanvas, and Moleculent also raising funds.
News CellCentric pockets $220m for blood cancer programme CellCentric has raised $220 million in a Series D financing that will help fund pivotal trials of p300/CBP inhibitor inobrodib in multiple myeloma.
Oncology ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C... At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
